Main Menu

Mylan N.V.



Attention investors who purchased shares of Mylan N.V. before July 29, 2019:

Rigrodsky & Long is investigating potential claims against the board of directors of Mylan N.V. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to merge with Pfizer Inc.

Press Release

Rigrodsky & Long, P.A. announces that it is investigating Mylan N.V. (“Mylan”) (NASDAQ GS: MYL) regarding possible breaches of fiduciary duties and other violations of law related to Mylan’s agreement to merge with Pfizer Inc. (“Pfizer”) (NYSE: PFE). Under the terms of the agreement, shareholders of Mylan will receive one share of Pfizer for each share of Mylan they own. Upon closing, shareholders of Mylan will own 43% of the combined company and shareholders of Pfizer will own 57% of the combined company.

If you would like to discuss this investigation and your rights cost and obligation free, please contact Seth D. Rigrodsky or Gina M. Serra toll free at (888) 969-4242 or by e-mail at

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Back to Page